共 60 条
[1]
Michalopoulos A(2005)Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis Crit Care 9 R53-R59
[2]
Kasiakou SK(2010)End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia in clinical trials: food and drug administration perspective Clin Inf Dis 51 S117-S119
[3]
Mastora Z(2004)Emerging resistance among bacterial pathogens in the intensive care unit–a European and North American surveillance study (2000–2002) Ann Clin Microbiol Antimicrob 3 14-601
[4]
Laessig KA(2006)Colistin: The re-emerging antibiotic for multi-drug resistant gram-negative bacterial infections Lancet Infect Dis 6 589-967
[5]
Jones ME(1999)Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria Ann Pharmacother 33 960-1155
[6]
Draghi DC(2010)Nebulized and intravenous colistin in experimental pneumonia caused by pseudomonas aeruginosa Int Care Med 36 1147-1244
[7]
Thornsberry C(2010)Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case–control study Clin Infect Dis 51 1238-1236
[8]
Li J(2010)Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study Clin Microbiol Infect 16 1230-322
[9]
Nationa RL(2008)CDC/NHSN surveillance definition of health-care associated infection and criteria for specific types of infections in the acute care setting Am J Infect Control 36 309-584
[10]
Turnidge JD(2010)Consensus summary of aerosolized antimicrobial agents: application of guideline criteria: insights from the society of infectious diseases pharmacists Pharmacotherapy 30 562-88